It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Lydia Usha, MD

Patient Feedback
Specialty:
  • Oncology, Medical
  • Internal Medicine
Board Certification:
  • Medical Oncology
Faculty Rank: Associate Professor
Medical or Graduate Education: St. Petersburg Institute of Public Health, Russia
Residency: California Pacific Medical Center - Internal Medicine
Fellowship: University of Illinois Medical Center - Hematology/Oncology
Clinical Expertise:
  • Breast cancer
  • Cancer risk assessment and counseling
  • Cervical cancer
  • Endometrial cancer
  • Genetic testing
  • Gynecologic cancer
  • Ovarian cancer
  • Uterine cancer
Research Interests:
  • Treatments for breast cancer
  • Treatments for gynecologic cancer
  • Screening, risk assessment, and management of hereditary predisposition to cancer
  • Clinical trials for gynecologic cancer
Languages Spoken:
  • Russian
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature.
    Katz DA, Abrams RA, Sclamberg JS, Usha L
    Pract Radiat Oncol
    2014 Oct 25
    :.
  2. Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress.
    Doscas ME, Williamson AJ, Usha L, Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, Williams JW, Li Y, Xu X
    Neoplasia
    2014 Oct
    16(10):824-34.
  3. TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.
    Ben Musa R, Usha L, Hibbeln J, Mutlu EA
    World J. Gastroenterol.
    2014 May 21
    20(19):5912-7.
  4. Mesenchymal stem cells develop tumor tropism but do not accelerate breast cancer tumorigenesis in a somatic mouse breast cancer model.
    Usha L, Rao G, Christopherson Ii K, Xu X
    PLoS ONE
    2013
    8(9):e67895.
  5. Hereditary inflammatory breast cancer associated with BRCA2 mutation: a rare disease presentation in mother and daughter.
    Jimenez AM, Growney A, Behrens G, Corbridge C, Chapman DD, Usha L.
    Clin Adv Hematol Oncol. 2012
    2012 Jun
    10(6):402-4. No abstract available.
  6. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
    Kunos C, Radivoyevitch T, Abdul-Karim FW, Fanning J, Abulafia O, Bonebrake AJ, Usha L.
    J Transl Med. 2012
    2012 Apr 27
    10:79. doi: 10.1186/1479-5876-10-79.
  7. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
    Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.
    Gynecol Oncol. 2011
    2011 Jun 1
    121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.
  8. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.
    Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS.
    J Hematol Oncol. 2008
    2008 Aug 14
    1:12. doi: 10.1186/1756-8722-1-12.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Friendliness/courtesy of the care provider
4.8
Explanations the care provider gave you about your problem or condition
4.8
Concern the care provider showed for your questions or worries
4.8
Likelihood of your recommending this care provider to others
4.8
Care provider's efforts to include you in decisions about your treatment
4.8
Information the care provider gave you about medications
4.8
Instructions the care provider gave you about follow-up care
4.8
Your confidence in this care provider
4.8
Degree to which care provider talked with you using words you could understand
4.8
Amount of time the care provider spent with you
4.7
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.